Literature DB >> 16547787

Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience.

Meryl Brod1, Soren E Skovlund, Kim U Wittrup-Jensen.   

Abstract

OBJECTIVE: Diabetes is a common, debilitating chronic illness with multiple impacts. The impact on treatment satisfaction, productivity impairment and the symptom experience may be among the most important for patient-reported outcomes. This study developed and validated disease-specific, patient-reported measures for these outcomes that address limitations in currently available measures.
METHODS: Data was collected from the literature, experts and patients and a conceptual model of the patient-reported impact of diabetes was created. Item pools, based on the conceptual model, were then generated. The items were administered to 991 diabetes patients via a web-based survey to perform item reduction, identify relevant factor structures and assess reliability and validity following an a-priori analysis plan.
RESULTS: All validation criteria and hypotheses were met resulting in three new, valid measures: a 21-item Satisfaction Measure (three sub-scales: burden, efficacy and symptoms), a 30-item Symptom Measure and a 14-item Productivity Measure assessing both life and work productivity impairments.
CONCLUSION: This triad of measures captures important components of the multifaceted diabetes patient experience and can be considered as valid, viable options when choosing measures to assess patient-reported outcomes. Addressing these outcomes may assist researchers and clinicians to develop more patient-centered diabetes interventions and care.

Entities:  

Mesh:

Year:  2006        PMID: 16547787     DOI: 10.1007/s11136-005-1624-6

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  24 in total

Review 1.  Understanding the choices that patients make.

Authors:  T R Taylor
Journal:  J Am Board Fam Pract       Date:  2000 Mar-Apr

2.  Satisfaction as a determinant of compliance.

Authors:  G Albrecht; J Hoogstraten
Journal:  Community Dent Oral Epidemiol       Date:  1998-04       Impact factor: 3.383

Review 3.  Quality of life and diabetes.

Authors:  R R Rubin; M Peyrot
Journal:  Diabetes Metab Res Rev       Date:  1999 May-Jun       Impact factor: 4.876

Review 4.  Barriers to good glycaemic control: the patient's perspective.

Authors:  F J Snoek
Journal:  Int J Obes Relat Metab Disord       Date:  2000-09

5.  Assessment of satisfaction with treatment for chronic pain.

Authors:  L M McCracken; P A Klock; D J Mingay; J K Asbury; D M Sinclair
Journal:  J Pain Symptom Manage       Date:  1997-11       Impact factor: 3.612

6.  Productivity and medical costs of diabetes in a large employer population.

Authors:  Scott Ramsey; Kent H Summers; Stephanie A Leong; Howard G Birnbaum; Jason E Kemner; Paul Greenberg
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

7.  Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

Authors:  H King; R E Aubert; W H Herman
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

8.  Assessment of diabetes-related distress.

Authors:  W H Polonsky; B J Anderson; P A Lohrer; G Welch; A M Jacobson; J E Aponte; C E Schwartz
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

9.  Fatigue in employees with diabetes: its relation with work characteristics and diabetes related burden.

Authors:  I Weijman; W J G Ros; G E H M Rutten; W B Schaufeli; M J Schabracq; J A M Winnubst
Journal:  Occup Environ Med       Date:  2003-06       Impact factor: 4.402

10.  Development and validation of the insulin treatment satisfaction questionnaire.

Authors:  Roger T Anderson; Soren E Skovlund; David Marrero; Douglas W Levine; Keith Meadows; Meryl Brod; Rajesh Balkrishnan
Journal:  Clin Ther       Date:  2004-04       Impact factor: 3.393

View more
  29 in total

1.  Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ).

Authors:  Jörn Moock; Franz Hessel; Diana Ziegeler; Thomas Kubiak; Thomas Kohlmann
Journal:  Patient       Date:  2010-03-01       Impact factor: 3.883

Review 2.  Can the Routine Use of Patient-Reported Outcome Measures Improve the Delivery of Person-Centered Diabetes Care? A Review of Recent Developments and a Case Study.

Authors:  Soren E Skovlund; T H Lichtenberg; D Hessler; N Ejskjaer
Journal:  Curr Diab Rep       Date:  2019-08-16       Impact factor: 4.810

3.  Evolving trends in insulin delivery in pursuit of improvements in diabetes management.

Authors:  Firas Akhrass; Nancy Skinner; Kimberly Boswell; Luther B Travis
Journal:  Am Health Drug Benefits       Date:  2010-03

Review 4.  Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.

Authors:  Tsuyoshi Ohkura
Journal:  World J Diabetes       Date:  2015-02-15

Review 5.  Management of Type 2 Diabetes - Methods for Addition of Prandial to Basal Insulin.

Authors:  W Rodbard Helena; Boris Karolicki
Journal:  Eur Endocrinol       Date:  2014-08-25

6.  Reliability and validity of an instrument for assessing patients' perceptions about medications for diabetes: the PAM-D.

Authors:  Patrick O Monahan; Kathleen A Lane; Risa P Hayes; Colleen A McHorney; David G Marrero
Journal:  Qual Life Res       Date:  2009-07-16       Impact factor: 4.147

7.  Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.

Authors:  S Shah; M Benroubi; V Borzi; J Gumprecht; R Kawamori; J Shaban; M Shestakova; Y Wenying; P Valensi
Journal:  Int J Clin Pract       Date:  2009-02-05       Impact factor: 2.503

8.  Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.

Authors:  Meryl Brod; Paul Valensi; Joseph A Shaban; Don M Bushnell; Torsten L Christensen
Journal:  Qual Life Res       Date:  2010-07-04       Impact factor: 4.147

9.  Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.

Authors:  J Gumprecht; M Benroubi; V Borzi; R Kawamori; J Shaban; S Shah; M Shestakova; Y Wenying; R Ligthelm; P Valensi
Journal:  Int J Clin Pract       Date:  2009-06       Impact factor: 2.503

10.  Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device).

Authors:  Meryl Brod; Mette Hammer; Torsten Christensen; Suzanne Lessard; Donald M Bushnell
Journal:  Health Qual Life Outcomes       Date:  2009-09-09       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.